来源：环球网 【环球网财经综合报道】据彭博社等外媒报道，丹麦制药巨头诺和诺德母公司Novo Holdings近日宣 布，其投资设立的量子专项风险投资基金"55 North"已完成首轮募资，募集金额约3亿欧元。该基金由 Novo Holdings与丹麦出口与投资基金(EIFO)共同作为基石投资者，合计出资1.34亿欧元，成为目前全球 规模最大的专注量子技术领域的风险投资基金。 （图片来源：彭博社） 据Novo Holdings披露，总部位于丹麦的55 North基金将立足北欧和欧洲，面向全球开展投资。目前基金 已参与两项重要投资：一是欧洲量子计算领军企业IQM最新一轮2.75亿欧元的B轮融资；二是向德国量 子计算机低温冷却系统供应商Kiutra注入千万级欧元资金。 今年早些时候，丹麦出口与投资基金(EIFO)与诺和诺德基金会共同出资8000万欧元，成立北欧量子合资 企业QuNorth，专注于采购、建造并运营名为"Magne"的商用量子计算机。该项目预计2027年初投入运 营，目标成为全球性能最强大的商用量子计算机之一。 诺和诺德基金会的量子科技布局始于2022年，已累计投入近3000万美元建设哥本哈根生物医学量 ...

55 North总部位于丹麦，将在全球范围内进行投资，并以北欧和欧洲为重点地区。目前该基金已参与了 两项投资。 近日，减重药司美格鲁肽厂商丹麦制药巨头诺和诺德母公司投资设立了量子专项风投基金55 North。该 基金在首轮募资中获得了约3亿欧元资金，其中，诺和诺德母公司Novo Holdings和丹麦出口与投资基金 （EIFO）作为基石投资者投资了1.34亿欧元。该基金也成为目前全球规模最大的量子专项风险投资基 金。 与此同时，诺和诺德也在加大对AI的投入。2024年，关于AI的讨论进入公司董事会议程，并且与研发 管线、公司战略以及重大并购一起列出，证明了人工智能对诺和诺德未来的战略重要性。 诺和诺德认为，AI在制药行业的应用不仅仅是通过单一的技术突破，而是通过精心策划一个自我强化 的"飞轮"。 今年，诺和诺德还与英伟达合作，加速药物研发。该合作将支持诺和诺德与丹麦人工智能创新中心共同 运营的丹麦旗舰人工智能超级计算机 Gefion。两家公司还宣布将专注于开发定制的人工智能模型，供 诺和诺德研究人员用于临床开发的早期阶段，并运行先进的模拟和物理人工智能技术。 对于人工智能和量子技术未来的结合，量子模拟领域顶尖 ...

Group 1 - The stock of Novo Nordisk (NVO) has decreased by 10.5% since the last analysis, indicating a potential deep value opportunity for investors [1] - There is a belief that the stock has reached its bottom, prompting consideration for purchasing shares [1] Group 2 - The analysis reflects a personal opinion of the author, who holds a long position in NVO and LLY stocks [2]

Core Insights - Over a quarter of American adults with diabetes used GLP-1 injection drugs last year, indicating a significant adoption of these medications for managing type 2 diabetes and weight loss [4] - The most common age group using these drugs is 50 to 64 years old, with a usage rate of 33.3%, reflecting a higher disease burden in this demographic [4] - The high cost of GLP-1 drugs, approximately $1,000 per month, has drawn criticism despite their effectiveness [6] Usage Statistics - Approximately 31% of insulin users also use GLP-1 drugs, while about 28% of oral hypoglycemic drug users do the same, suggesting GLP-1 therapy is increasingly integrated into combination treatment plans [6] - Among different ethnic groups, Hispanic diabetic adults have the highest usage rate of GLP-1 drugs at 31.3%, followed by non-Hispanic Black at 26.5% and non-Hispanic White at 26.2%. Non-Hispanic Asian adults have the lowest usage rate at 12.1% [6] Drug Mechanism - GLP-1 drugs mimic the action of hormones that regulate blood sugar levels, delay digestion, and prolong feelings of fullness, contributing to blood sugar control and weight loss [6][15]

整理 | GLP1减重宝典内容团队 根据9月10日发表在《新英格兰医学杂志》上的结果，在后期临床试验中， 司美格鲁肽（Ozempic）前代药物利拉鲁肽（ Saxenda） 被证明可 以降低 6 至 11 岁肥胖儿童的体重指数。 这一发现将最新的强效减肥药这一现象（以及争议）带入了 迄今为止年龄最小的人群 。除了治疗导致肥胖的罕见遗传疾病的药物外，12 岁以下 儿童的肥胖症没有其他药物可供选择。 这项新试验研究了利拉鲁肽，这是诺和诺德两种较老的 GLP-1 药物中使用的活性成分：减肥药 Saxenda 和糖尿病药物 Victoza。司美格鲁肽也 是诺和诺德的另一种 GLP-1 药物，是Ozempic 和 Wegovy中的药物活性成分。 其 所有产品均适合终身使用。 Fox 说，要弄清这种药物的效果并不像测量体重减轻那么简单，因为孩子们仍在成长，而且每个孩子的成长速度都不同。因此，他们决定更多地 关注 BMI，而不是像成人研究那样关注整体体重减轻，BMI 同时考虑了体重和身高。 她说："5 磅的变化对 6 岁孩子和 10 岁孩子来说是非常不同的。" 56 周后，服用 利拉鲁肽 的儿童 BMI 平均下降 5.8% ...

Shoppers associate Costco with value. Now a new deal. Novo Nordisk partnering with the popular warehouse chain to offer its 120 million members the weight loss drug WGOI and the diabetes drug OMIC for about half the price when paying out of pocket.Why have you decided to do this. Because we want to make sure we offer the real authentic WGOi and OMIC where patients seek care. And we know that Costco is a trusted brand.You won't be able to pull the drugs off the shelf like rolls of paper towels. You will need ...

I wrote back in January that I believed the drug stocks would outperform the general stock market for the first time in years in 2025 . The rationale was quite simple-valuations were conservative yetAnalyst’s Disclosure:I/we have a beneficial long position in the shares of LLY, AZN, NVO, PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business re ...

Core Insights - Danish drugmaker Novo Nordisk plans to make its new obesity pill available through telehealth platforms like Ro and WeightWatchers upon receiving U.S. approval [1] Company Strategy - The company is focusing on expanding access to its obesity treatment through digital health platforms, indicating a shift towards telehealth solutions in the pharmaceutical industry [1] Market Implications - The move to utilize telehealth platforms suggests a growing trend in the healthcare sector towards integrating technology with traditional treatment methods, potentially increasing patient engagement and adherence [1]

Company Strategy - Novo Nordisk plans to launch its new obesity pill on telehealth sites [1] - Telehealth sites include Ro and WeightWatchers [1] Product Pipeline - The launch is planned as soon as the new obesity pill is approved [1]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I thought I would do something different for my column today. I will try to peer out into the next year and make three way-too-early predictions for 2026. They follow below.Bret leads the investing group The Biotech Forum , in which he ...